Last week, Cantor's Capital Introduction team hosted its inaugural Biotech Panel, moderated by Senior Managing Director and Senior Biotechnology Analyst, Eric Schmidt, Ph.D. Panelists shared their insights on the latest trends and future directions in biotechnology, discussing groundbreaking therapies, diagnostics, and innovative solutions driving the sector forward. A special thank you to our panelists for their invaluable contributions to the success of this event: Anna Cosslett Yaeger, Partner & Head of Public Equities of 5AM Ventures; Vincent Aita, CIO & Managing Partner of Cutter Capital Management, LP; Kevin Pyun, CIO of Dellora Investments; and Rod Wong, CIO & Managing Partner of RTW Investments, LP. If you missed the panel or are interested in learning more about Cantor Prime Services and our Capital Introduction capabilities, please reach out to us here: https://lnkd.in/eB6TnVmE.
Cantor Fitzgerald’s Post
More Relevant Posts
-
Women's Health Forecaster | Speaker | Trend Expert | "Trailblazing Leader in FemTech" - Women of Wearables
Well deserved! Very proud to have spotted this trend early on and featured BoobyBiome in our report last year: FemTech Futures 30: The 30 most influential trends shaping the market in 2024. In it we said: "BoobyBiome uses bacteria sourced from breast milk donated by healthy mothers. While the gut microbiome has been gaining attention in recent years, research around baby microbiomes is only just reaching public consciousness. As awareness spreads, we expect to see new regulations around microbiome-based products and therapeutics, which will give parents the peace of mind required to feed their babies probiotics and explore additional solutions for securing their healthy futures." Read the full report here: https://lnkd.in/ebCEdPg6 #trendforecasting #womenshealthtrends #trends2024 #womenshealth #femtech
I’m incredibly proud to announce that we’ve secured a £1.6M Biomedical Catalyst grant to test and scale up our BoobyBiome Synbiotic. A huge thank you to Innovate UK for their continued support. We’re also thrilled to welcome our new investors, Evenlode Investment, Kayan Ventures, and a group of angel investors. A huge shout out to Lydia Mapstone, PhD, Tara O'Driscoll, PhD, Megan Powell, Catherine Gurr, Rozalyn Yorke, and Ryan Ames - I can’t wait to reach this next milestone together.
To view or add a comment, sign in
-
Not long after the official divestment of GRAIL, Illumina have now officially acquired single cell multi-omics player Fluent BioSciences Inc.! We feel Illumina are telegraphing their intentions to increase dominance within the growing single cell multi-omics sector, which is poised to hit a market value of$𝟯𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟯 👀📈 We wish both Illumina & Fluent BioSciences Inc. the utmost success 🫱🏽🫲🏼 #acquistion #multiomics #masonhardingnews
To view or add a comment, sign in
-
Join Laia Pascual Ponce (Ship2B Ventures), Fabrizio Conicella (Chiesi USA, Inc.), Salvatore Cappadona (Criteria Bio Ventures), Anna Bellmunt (Asabys Partners), Kerstin Papenfuss, PhD MBA, (Deep Science Ventures) and Alejo Chorny, (AdBio partners) at RESI Europe 2024, June 17-19, a hybrid conference, in-person (June 17), and online partnering (June 18-19), for the Early Stage Therapeutics Panel. The moderator will guide the discussion through topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization. Register: https://lnkd.in/dhxge-zb #RESI #RESIEUROPE #RESIBARCELONA Biocat, BioRegion of Catalonia Biotechgate
To view or add a comment, sign in
-
We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said. We are innovative: We are inquisitive and resourceful. Each day we solve problems, think outside the box and push boundaries in the pursuit of delivering novel therapeutics. Our science is stellar, enabling us to not only identify the target but also understand how it interacts with its native ecosystem, separate from the confounding complexity of the cell. We do high-quality science on a daily basis! Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery
To view or add a comment, sign in
-
BGPartner advises Novo Holdings, EQT, OrbiMed and SR One on $100 mio Series C financing of Asceneuron SA Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One Capital Management, alongside participation from existing investors Merck Serono S.p.A., Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease. BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information can be found here: https://lnkd.in/d278vevG More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw #Financing #swiss #Biotech #law #negotiation #Alzheimer
To view or add a comment, sign in
-
💰🤑💹 Let's brighten up your Friday with another round of big investment news. We're seeing a decrease in the amount of 9 figure investments for the Biotech industry this week, but given how much was invested in Q1 this isn't too much of a surprise. Watch my video to hear who the movers and shakers are this week: 💵 Asher Biotherapeutics - $55 million Series C 💳 DeepCure - $25 million Series A 💸 Corner Therapeutics - $54 million Series A 💲 Pathios Therapeutics - $25 million Series B 💷 Theolytics - £19 million #financialfridays #biotechinvestment #vcinvestment #venturecapitalist
To view or add a comment, sign in
-
Our CEO Ashley Zehnder will be speaking at the LSX USA Congress in Boston this Thursday, September 12, 11:00am - 11:50am at the Hynes Convention Center. What is Required to Scale? Fast-Tracking Biotech Growth When transitioning into a growth-stage biotech, it’s important to consider your strategy top succeed. Biotech companies needing to address unmet medical needs, without careful evaluation of market potential, there is a risk of failure. Staying virtual and outsourcing work to CROs vs building and carrying out in-house research Most important factors to remember when scaling up The people factor in building and growing business The panel will be moderated by Jenny Holt, Chief Development Officer, Ray Therapeutics, Inc. and include speakers: Vik Chawla, Managing Director, Portfolio Strategy & Transactions, Syneos Health Samta Kundu, COO, Strand Therapeutics Wyatt McDonnell, CEO, Infinimmune, Inc. Ashley Zehnder, Ph.D., CEO, Fauna Bio Minji Kim, CBO, Mineralys Therapeutics, Inc. More info here: https://lnkd.in/eQjBmQCb
To view or add a comment, sign in
-
Try, try again: Longevity biotech targets public listing via SPAC for the second time After scrapping initial SPAC deal, Longevity Biomedical, Inc. aims to list on Nasdaq in Q4 through business combination agreement with FutureTech. #longevity #biotech #investment #SPAC
Try, try again: Longevity biotech targets public listing via SPAC for the second time
https://longevity.technology
To view or add a comment, sign in
-
Did you miss our Q4 Earnings Call? Do you want to hear about our increasing sales, an update on the US sales, the newest commercial agreements, and growth in our Pharma Portfolio? Due to time constraints we did not manage to address all questions we received during the meeting, but you will find it in writing with the recording. Watch the recording and read the Q&A document here: https://loom.ly/ADFKOcg Presenters: Anders Rylander, CEO Anders Morén, CFO Henrik Winther, SVP Business Development Hector Tamburini, Head of US Operations #biovicb #investors #oncology #nasdaqfirstnorth
To view or add a comment, sign in
-
Follow this thread over the coming days to find out the 15 reasons OMass Therapeutics is Fierce!
We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said. We are innovative: We are inquisitive and resourceful. Each day we solve problems, think outside the box and push boundaries in the pursuit of delivering novel therapeutics. Our science is stellar, enabling us to not only identify the target but also understand how it interacts with its native ecosystem, separate from the confounding complexity of the cell. We do high-quality science on a daily basis! Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery
To view or add a comment, sign in
120,137 followers